NANEXA AB (PUBL) Inactive Instrument
Nanexa AB (publ) Stock Nasdaq Stockholm
Equities
SE0007074166
Medical Equipment, Supplies & Distribution
| Sales 2024 * | 71.3M 6.51M | Sales 2025 * | 69.5M 6.35M | Capitalization | 109M 9.91M |
|---|---|---|---|---|---|
| Net income 2024 * | 16M 1.46M | Net income 2025 * | -4M -365K | EV / Sales 2024 * | 0.6 x |
| Net cash position 2024 * | 65.5M 5.98M | Net cash position 2025 * | 82M 7.49M | EV / Sales 2025 * | 0.38 x |
| P/E ratio 2024 * |
20
x | P/E ratio 2025 * |
3.64
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nanexa AB (publ)
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Mårten Rooth
FOU | Founder | 47 | 06-12-31 |
Anders Johansson
FOU | Founder | 48 | 06-12-31 |
David Westberg
CEO | Chief Executive Officer | 64 | 15-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 20-06-01 | |
| Director/Board Member | 69 | 22-12-31 | |
| Corporate Officer/Principal | 62 | 14-12-31 |
Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.
Calendar
2024-05-02
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -62.37% | 78.84M |
